US-China Clinical Trial Regulatory Overview
Innovative Chemical Drug Development in China
December 21, 2019
China Annual ADR & ADE Monitoring Report (2018)
December 26, 2019
In this publication, we give a side-by-side comparative overview of clinical trial regulatory commonalities and differences between the US and China. This is a must-read if you plan to enter your pharmaceutical and medical products into the world’s two largest healthcare markets.
In this report we use intuitive tables to list and compare in details the key functions in these areas between the US and China:
- Regulatory authority
- Clinical trial registration scope
- Clinical trial process
We will also provide some key takeaways from our practice in the US-China dual/parallel registration and clinical trial work.
Click here to receive this CR Medicon publication: US-CHINA CLINICAL TRIAL REGULATORY OVERVIEW
Also subscribe to our CRO newsletter to receive current development, events, and reports like this from our industry:
About Us
CR Medicon (https://en.crmedicon.com) provides innovative pharma and biotech companies with comprehensive clinical development services, including drug registration, medical affairs, clinical operations, data management & statistical analysis, and biological sample analysis. We are China’s most well-known clinical CRO partner, for both domestic and overseas companies. CR Medicon team consists more than 200 full-time employees with clinical sites in both USA and China. Contact us at +1 (732) 624-9052 or email biz@crmedicon.com.
